Knome

Tute will offer interpretation and annotation software from Knome's KnoSys appliance as part of its existing cloud offering but is open to providing a local option for interested clients.

Under the terms of the purchase agreement, Tute is integrating Knome's KnoSys technology with Tute's cloud-based genome informatics and clinical reporting platform.

The companies will combine Genalice's data processing software with Knome's genome interpretation platform.

NEW YORK (GenomeWeb) – Genalice and Knome said today that the Swiss Foundation for People with Rare Diseases has selected both companies' solutions to process and analyze their next-generation sequencing data.

NEW YORK (GenomeWeb) – Knome said today that it has joined the Global Alliance for Genomics and Health (GAGH), a global effort to responsibly share and analyze large quantities of genomic and clinical data.

NEW YORK (GenomeWeb) – Knome today announced a sponsorship agreement to offer its next-generation sequencing data analysis system to startups in LabCentral's facility for free.

The organizers of the sbvIMPROVER project have released a set of comprehensive biological models for chronic obstructive pulmonary disease for review by the global scientific community.

Knome has hired Josh Forsythe as its new vice president of sales and marketing. He joins the company after 10 years at Golden Helix, where held several positions including VP of business development, VP of sales and marketing, and director of marketing.

This week, Gentle said that it has expanded its portfolio to include InHelix, a new genome interpretation service, which the Leuven, Belgium-based company has launched to help medical geneticists and clinicians annotate and identify both novel and known pathogenic variants that u

NEW YORK (GenomeWeb News) – Knome and Personal Genomics today announced an exclusive sales agreement and a scientific partnership covering Knome's knoSys platform.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.